FDA Approves Buprenorphine Injection for Opioid Use Disorder

The FDA has approved extended-release injection buprenorphine (Brixadi, Braeburn Inc) for the treatment of moderate to severe opioid use disorder.

Related Keywords

Robertm Califf , , Mental Health Services Administration , Braeburn Inc , Drug Administration , Overdose Prevention Framework , Substance Abuse , Risk Evaluation , Mitigation Strategy , Addiction , Opioids , Abuse , Adverse Effects , Side Effects , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Nausea , Spain , Pruritus , Pruritis , Pitch , Risk Evaluation And Mitigation Strategies Rems , Patient Safety , Constipation , Headache , Insomnia , Pain Management , Practice Management , Sleep Disorder , Urinary Tract Infection Uti , Rinary T ,